Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | LDHA | P00338 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 3/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334385 | 0.90 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL1586263 | 0.90 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL9633193 | 0.90 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL1586261 | 0.90 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL334384 | 0.90 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL16767542 | 0.90 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL13354941 | 0.90 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL7253275 | 0.88 | SLC6A4 (0.63) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL14534146 | 0.88 | SLC6A4 (0.63) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL14534147 | 0.88 | SLC6A4 (0.63) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462746-B2 | Amino polyols and amino sugars | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2008-12-09 | — | — | US | claimed |
| EP-0923544-B1 | METHOD FOR THE SYNTHESIS OF AMINES AND AMINO ACIDS WITH ORGANOBORON DERIVATIVES | UNIV SOUTHERN CALIFORNIA (US) | 2008-10-15 | — | — | EP | claimed |
| US-20040053330-A1 | Amino polyols and amino sugars | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-18 | — | — | US | claimed |
| JP-59070663-A | — | — | None | — | — | JP | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-4556514-A | INTERMEDIATES FOR PRODUCTION OF CARBAPENEM OR PENEM DERIVATIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-12-03 | — | — | US | disclosed |
| US-4536334-A | Preparation of β-lactam derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-08-20 | — | — | US | disclosed |
| EP-0064797-B1 | N-DIARYLMETHYL-3-AMINO-4-ALKENARYL-2-AZETIDINONES AND THEIR PREPARATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-05-22 | — | — | EP | disclosed |
| EP-0023097-B1 | DE-ARYLMETHYLATION OF N-MONO- OR N-DIARYLMETHYL-BETA-LACTAMS; NOVEL AZETIZINONES HAVING ANTI-BACTERIAL ACTIVITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-08-01 | — | — | EP | disclosed |
| EP-0106652-A1 | Beta-lactam compounds and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1984-04-25 | — | — | EP | disclosed |
| JP-S5970663-A | PREPARATION OF BETA-LACTAM DERIVATIVE | SUMITOMO CHEM CO LTD | 1984-04-21 | — | — | JP | disclosed |
| EP-0070204-A2 | Carboxylic beta-lactam compounds and the preparation thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1983-01-19 | — | — | EP | disclosed |
| EP-0064797-A1 | N-Diarylmethyl-3-amino-4-alkenaryl-2-azetidinones and their preparation | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-11-17 | — | — | EP | disclosed |
| EP-0023097-A1 | De-arylmethylation of N-mono- or N-diarylmethyl-beta-lactams; novel azetizinones having anti-bacterial activity | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053330-A1 | Amino polyols and amino sugars | STT3B, METTL3, GFPT1 | SLC6A4 1155/4885CYP1A2 2901/4885CYP2D6 1381/4885 |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | SLC6A4 2870/4885CYP1A2 2143/4885CYP2D6 2285/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | SLC6A4 2870/4885CYP1A2 2143/4885CYP2D6 2285/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | SLC6A4 2870/4885CYP1A2 2143/4885CYP2D6 2285/4885 |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | SLC6A4 2870/4885CYP1A2 2143/4885CYP2D6 2285/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | SLC6A4 2870/4885CYP1A2 2143/4885CYP2D6 2285/4885 |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | SLC6A4 2870/4885CYP1A2 2143/4885CYP2D6 2285/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | SLC6A4 2870/4885CYP1A2 2143/4885CYP2D6 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.